ROCCA, ANDREA
 Distribuzione geografica
Continente #
EU - Europa 264
AS - Asia 260
NA - Nord America 191
SA - Sud America 5
AF - Africa 4
OC - Oceania 1
Totale 725
Nazione #
CN - Cina 216
US - Stati Uniti d'America 187
IT - Italia 154
FR - Francia 49
IN - India 16
UA - Ucraina 12
DE - Germania 10
GB - Regno Unito 9
NL - Olanda 8
FI - Finlandia 7
JP - Giappone 6
IQ - Iraq 5
BR - Brasile 4
HK - Hong Kong 4
PR - Porto Rico 4
SE - Svezia 4
SN - Senegal 3
AT - Austria 2
BD - Bangladesh 2
ID - Indonesia 2
KR - Corea 2
PT - Portogallo 2
TW - Taiwan 2
AU - Australia 1
CH - Svizzera 1
ES - Italia 1
GR - Grecia 1
IR - Iran 1
MK - Macedonia 1
NG - Nigeria 1
PE - Perù 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
RS - Serbia 1
SG - Singapore 1
TH - Thailandia 1
VN - Vietnam 1
Totale 725
Città #
Beijing 180
Columbus 94
Trieste 49
Ashburn 20
Boardman 20
Rome 10
Monfalcone 9
Milan 8
New York 6
Washington 6
Paris 5
Council Bluffs 4
Guayama 4
Lappeenranta 4
Messina 4
Mumbai 4
Amsterdam 3
Basrah 3
Chicago 3
Hong Kong 3
Naples 3
Noida 3
Pune 3
Yongzhou 3
Aversa 2
Bengaluru 2
Cardiff 2
Chieti 2
Conley 2
Fulham 2
Gioia del Colle 2
Helsinki 2
Innsbruck 2
Irschenberg 2
London 2
Los Angeles 2
L’Aquila 2
Marseille 2
Mestre 2
Newcastle upon Tyne 2
Osaka 2
Ovar 2
Realeza 2
Roncade 2
Shanghai 2
St Louis 2
Sukabumi Utara 2
Teramo 2
Tolmezzo 2
Uppsala 2
Anzio 1
Asaba 1
Baghdad 1
Bagnolet 1
Bangkok 1
Bergamo 1
Binetto 1
Bitola 1
Boston 1
Brisbane 1
Cambridge 1
Casamarciano 1
Cesena 1
Chittagong 1
Clifton 1
Cricklewood 1
Daejeon 1
Dakar 1
Dhaka 1
Falkenstein 1
Fontainebleau 1
Forlimpopoli 1
Frankfurt am Main 1
Genoa 1
Gurugram 1
Halethorpe 1
Ho Chi Minh City 1
Holden 1
Honolulu 1
Imola 1
Istrana 1
Karachi 1
Karbala 1
Krakow 1
Leesburg 1
Lima 1
Lodi Vecchio 1
Ludwigshafen am Rhein 1
Montagny 1
Montereale Valcellina 1
Nashville 1
Nea Palatia 1
New Taipei 1
Niterói 1
Novara 1
Numata 1
Nuremberg 1
Okayama 1
Perugia 1
Pozzuolo del Friuli 1
Totale 553
Nome #
Can Systems Biology Advance Clinical Precision Oncology?, file 79169c83-3bcf-4013-8784-46cc1f8dbfd1 54
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report, file 82df134a-3361-45aa-a354-1b1e0bde9d6d 43
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study, file d5ae5eff-39c2-4560-b0d0-1afb97058627 35
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets, file 74eb81ad-b44e-442d-a9c3-0123e5b39733 32
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ, file 50ca7c60-ee3a-42e6-aec0-3dd9d28981f2 31
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy, file 9abb1102-f5a1-4271-aa9d-37a2e7b9cc27 31
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer, file 7b36fe54-f246-4344-9197-9f8959d3a91a 29
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer, file 306c6cd8-3810-4e24-a503-7c1d9f264c3b 28
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report, file baaeea82-33e4-42b1-b823-2fd0c236074a 27
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial, file 071393c5-cf87-465e-ba59-d43bc6e8f94a 25
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab, file 4d77b6f2-1bea-42f1-9c35-35bc7fd07528 22
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer, file ed2c4786-22ef-40b3-82cf-569c5838b856 21
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma, file bdba64bb-e983-45c6-aa76-8ae24138e84d 19
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience, file 31966d82-3f4e-4f0a-99ac-547aecb23cd6 18
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer, file 98fbf855-8c0c-4802-9dee-864951bee393 18
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), file fd939f6e-53ad-4dbe-b661-91a42573210c 18
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis, file 13fc3e38-d4cc-467f-9095-7069e62ac0d8 17
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT, file 9ef6b968-7d8a-42e5-a8c4-0f282757e22f 17
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma, file 2992acdd-b95b-43b3-8940-ef3354ad7513 15
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial, file 08101988-febe-415a-a594-2351bb54a6a0 13
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), file 38a14265-571f-46b8-b99c-bb09decd1e69 13
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab, file 69bd0fdb-7217-462b-8a8c-3e9dd2726e86 13
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report, file 2baf5848-1de7-4dc0-86a0-29a7269536f6 12
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial, file 50f1df54-179f-41a5-9c67-f155613ea3f4 12
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report, file 6ebf9d5b-96c1-442f-95f8-f99ba4e97921 12
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab, file 9ad49701-f9e4-4f3b-8b9e-d75db46b2c12 12
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer, file 33eed80a-9ab4-4569-bc07-b143e4a33bc1 11
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET), file e2913fdf-b866-f688-e053-3705fe0a67e0 11
Precision medicine: PI3K targeting in advanced breast cancer, file e8ca8c3e-ba0f-4113-9509-49790d0e9a30 11
Ribociclib and Endocrine Therapy in Breast Cancer, file 188dc294-205c-4179-b609-c8cf08aae0ba 10
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter, file bc0a4baa-ae32-4490-b55b-26df60422aed 10
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?, file 8e34723d-213d-4b44-b9f8-cc12c2e71ffd 9
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?, file d28c1ece-76d1-40b7-aa85-fcd0907617d9 9
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer, file 7476bbd1-15c3-4d68-9f42-4d993892b2a5 8
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?, file d1249145-5785-4267-b75b-8ca36a28edf8 7
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma, file a4fd1271-7da6-4314-951a-e5fb7cdf31f8 6
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study, file f94f4bbe-1970-4cfe-a2be-617ac4fd29e2 6
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer, file 2f7b32c2-8af3-4f31-a02c-159be276fb6d 4
Ribociclib and Endocrine Therapy in Breast Cancer, file 3b38af05-5837-498e-8b80-3133e5570d22 4
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial, file 42e4b0b0-fb91-40d9-a51d-ee7ecea51453 4
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT, file 4bc0a9f3-96f7-4d3b-9199-558196de7bc8 4
Precision medicine: PI3K targeting in advanced breast cancer, file 4e2b3c85-a470-47a1-b974-e34117900f8f 4
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study, file 9f71c623-2c16-483f-8516-cd4478938014 4
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?, file 4588e209-47db-41f2-9394-211d88880b3e 3
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter, file ebd72d83-417b-44fe-b66f-25b468662b2d 3
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer, file e2913fdb-608f-f688-e053-3705fe0a67e0 2
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings, file e2913fdf-705b-f688-e053-3705fe0a67e0 2
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial, file 1b2341ef-e3b1-43b1-a997-bbf26b15831b 1
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer?, file 1e571f80-1966-4f34-977f-d2886bb89c70 1
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy, file c14886b1-b07f-4a39-81bf-0e011efd67cf 1
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial, file c86708eb-1f6d-45bd-a28a-1b6a92de2431 1
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET), file e2913fdf-6a17-f688-e053-3705fe0a67e0 1
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma, file e2913fdf-c035-f688-e053-3705fe0a67e0 1
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer?, file f9c7b359-d2a6-45d9-aa2d-7e0f2015bd9f 1
Totale 726
Categoria #
all - tutte 2.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.274


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 0 0 3 1 0
2022/2023137 0 1 0 2 3 8 1 21 44 3 36 18
2023/2024583 18 19 19 33 13 45 89 140 27 49 125 6
Totale 726